Dose (mg/kg b.wt) | MST | AST | % IMLS | % IALS | % T/C ratio |
---|
DLA Control | 15.0 ± 1.57 | 15.2 ± 1.46 | – | – | – |
DLA + MMAE50 | 21.0 ± 1.50** | 21.3 ± 1.34** | 40.0 ± 1.57b | 40.7 ± 2.35b | 140.0 ± 2.57⋆ |
DLA + MMAE100 | 29.5 ± 1.28*** | 27.3 ± 1.91*** | 96.6 ± 1.88c | 80.1 ± 1.96c | 196.6 ± 3.33⋆ |
DLA + MMAE150 | 24.0 ± 1.52*** | 22.5 ± 1.04** | 60.0 ± 2.00a | 46.4 ± 2.56b | 160.0 ± 2.80⋆ |
DLA + DOX0.5 | 22.5 ± 1.50** | 24.2 ± 1.56*** | 63.3 ± 2.35a | 59.4 ± 1.86a | 163.3 ± 2.48⋆ |
- DLA Control: DLA bearing mice without treatment; DLA + MMAE50, DLA + MMAE100, DLA + MMAE150: DLA bearing mice treated with aqueous extract of M. macrophylla at the dose of 50, 100 and 150 mg/kg, respectively. DOX0.5: DLA bearing mice treated with doxorubicin (0.5 mg/kg). The results were expressed as percent (%) ± SEM, n = 10
- **p ≤ 0.01; ***p ≤ 0.001between the control and treatment groups
- Different letters indicates significant variation between different treatment groups
- ⋆ T/C ratio > 120